Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192352 | 0.90 | — | — | |
| SCHEMBL26453292 | 0.90 | — | — | |
| SCHEMBL26459073 | 0.88 | — | — | |
| SCHEMBL26096688 | 0.86 | KLKB1 (0.31) | DGAT1KLKB1 | |
| SCHEMBL29262495 | 0.85 | DGAT1 (0.32) | DGAT1KLKB1 | |
| SCHEMBL26453177 | 0.85 | LPL (0.33) | DGAT1 | |
| SCHEMBL16608469 | 0.83 | FFAR1 (0.32) | DGAT1 | |
| SCHEMBL26096300 | 0.83 | — | — | |
| SCHEMBL26092546 | 0.82 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL24896769 | 0.82 | CYP1A2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617798-B2 | Imidazopyrazne derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-05 | — | — | US | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4370514-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230203047-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4157846-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| CN-115667266-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | DGAT1 4530/4885KLKB1 3964/4885 |
| US-12617798-B2 | Imidazopyrazne derivatives | CLIC1, HCFC1, CXCR1 | DGAT1 4147/4885KLKB1 4523/4885 |
| US-20230203047-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | RPS4X, PYM1, RPS4Y1 | DGAT1 4866/4885KLKB1 3995/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | DGAT1 4522/4885KLKB1 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.